Secondary Hyperparathyroidism Due to Renal Causes Clinical Trial
Official title:
Changes of Pulmonary Function, Voice and Swallowing Symptoms After Total Parathyroidectomy for Secondary Hyperparathyroidism in the Presence of Intact Recurrent Laryngeal Nerve
In this study, investigators measure patient's voice frequency, swallowing function, and O2 desaturation of the 6 mins walking test before surgery and 4 months after surgery, to find the increase of voice frequency, and swallowing function and the decrease of O2 desaturation.
This was a prospective case-control study. From July 2017 to Dec. 2018, investigators
recruited 38 patients, who had undergone a successful operation of total parathyroidectomy
and bilateral thymectomy (TPxBT) plus autotransplantation for symptomatic secondary
hyperparathyroidism as the study group. In the same period 4 patients who had a surgical
failure were excluded from the study. Indications for surgery were patients who had undergone
long-term regular hemodialysis or continuous ambulatory peritoneal dialysis (CAPD), with
serum levels of Ca > 10.1 mg/dL, P > 5.5 mg/dL, alkaline phosphatase (Alk-ptase) > 94 U/L and
intact parathyroid hormone(iPTH) > 800 pg/mL and with symptoms and signs such as skin
itching, bone pain, general weakness, insomnia and T-score of bone mineral density (BMD) (the
lowest T-score of lumbar spine 1-4, global femur, femoral neck, radial 1/3, and global
radius) < -2.5. During surgery, Total parathyroidectomy and bilateral thymectomy was
performed plus autotranplantation of 100 mg of hyperplastic parathyroid tissue to the
subcutaneous tissue of the forearm without harboring an arteriovenous fistula.
Ten patients with regular hemodialysis who had developed mild secondary hyperparathyroidism
(iPTH around 500 pg/mL) but did not undergo parathyroidectomy were recruited as the control
group.
Investigators recorded patients' age, symptoms, gender, body mass index (BMI) and measured
serum levels of Ca, P, Alk-ptase and iPTH, and BMD (T-score). The Investigators also recorded
patients' voice quality, airway invasion during swallowing and pulmonary functions before
surgery and 4 months after surgery to find the changes after surgery. In the control group,
investigators recorded and measured these items at baseline and 4 months later.
At 1 week after surgery, serum Ca, P, Alk-ptase and iPTH levels were measured again to make
sure that the operation was successful. A successful operation was defined as iPTH levels <
72 pg/mL within 1 week after surgery. Four patients were excluded from this study with a
surgical failure in the same period.
The perceptual evaluation of voice quality such as speech impairment and speech quality by
means of multidimensional clinical measurements based on auditory methods with grade,
hoarseness, roughness, breathiness, asthenia, and strain (GRBAS) on a scale (0-3)
(normal-high degree) were performed by the ear, nose, and throat specialist (Dr. Lai, C.C.).
Voice handicap index (VHI-10) (>11, abnormal) and eating assessment tool (EAT-10) (≥ 3,
abnormal) were evaluated by patients themselves.
Acoustic and aerodynamic measurements were applied to recordings of each subject producing
sustained vowel productions in a soundproof room. Acoustic variables including jitter (Jitt),
shimmer (ShdB), noise-to-harmonic ratio (NHR), fundamental frequency (Fo), and high pitch
were measured using computerized speech laboratory (Core Model SCL # 4300B, KayPENTAX
Elementries, Lincoln park, NJ).
The maximal phonation time and s/z ratio were measured with circumferentially vented
pneumotachography mask and differential transducers of the Aerophone system (Aerophone II,
Model 6800, KayPENTAX Elementrics). Vocal cord mobility, vocal cord closure (complete or
incomplete), airway invasion during swallowing were inspected with fiber-optic endoscopy to
show premature spillage, penetration-aspiration scale levels (1-8) (no entry of material into
the larynx or trachea-material enter the airway passes below vocal folds and no effort is
made to eject) (>1, abnormal). The Yale pharyngeal residue severity rating scale for
vallecula (0-4) (non-trace-mild-moderate-severe) and pyriform sinus (0-4) were also performed
by the ENT specialist.
The specialist of chest medicine (Dr. Chang, H.C.) performed pulmonary function tests
including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1),
bronchodilator test (BDT) (a positive response to BDT defined by the American Thoracic
Society as an increase in FEV1 or FVC ≥ 12% and 200 ml), total lung capacity (TLC), and
alveolar volume (VA) using MasterScope (Jaeger, VIASYS healthcare GmbH, Höchberg, Germany),
and diffusion capacity of the lung for carbon monoxide (DLCO) using Vmax Autobox
(SensorMedics, a subsidiary of VIASYS healthcare, California, USA). The 6 minutes walking
test (6MWT) was also performed to evaluate distance (meter) and O2 desaturation (differences
of O2 saturation between pre- and post-tests) (defined as positive if O2 desaturation ≧ 4%).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03588884 -
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency
|
Phase 4 | |
Active, not recruiting |
NCT03602261 -
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
|
Phase 2 | |
Completed |
NCT01939977 -
Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.
|
Phase 4 | |
Recruiting |
NCT05549154 -
A Study on Prevention Strategies for CKD-SHPT and Related Complications Based on General Vitamin D Supplementation
|
N/A |